Skip to content

JELY PHARMA

Active
Private limited companyfounded 201511 yrs activeRue du Jardinier 8, 1315 Incourt, BelgiumKBO/BCE: BE 0635.630.013
Summary

JELY PHARMA has been active since 2015 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €381 and a net result of €20,540. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 13% of 4911 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.0% (low).

Risk analysisWatch ReportCompare
JELY PHARMAActiveChecked score 65/100
Risk analysis ReportCompare

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€469,684total assets 2025
Staff
1.6 FTE
Equity
€381
Profit
€20,540
Financial health
65 Healthy Checked score 2025
Bankruptcy chance 12 m
1.0%
Structure
Holdings
1
Accounts 121 d early0 of 4 deeds read
Why 65- Equity €381 (0.1% of total assets)- 1 of the last 3 late+ Founded in 2015+ Size: 1.6 FTE, total assets €469,684Show the evidence

Checked score

Score 2025
65 / 100
Healthy
Probability in this band: 0.55% to 1.5%
Better than 33% of its sector peers (NACE 47, micro)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Average
Solvency 25-7
equity 0.1% of total assets
Liquidity 47+7
short-term debt 52.8% · cash 19.1%
Profitability 74+1
return on assets 4.4%
Bankruptcy probability, 12 months
1.0% Low
0%0.5%1.5%4%10%≥ 25%

About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,158 companies)
Last 24 months 11-2024: 1.4% 12-2024: 1.3%▼ -0.7% vs 11-2024 01-2025: 1.3%▼ -1.3% vs 12-2024 02-2025: 1.3%▼ -5.4% vs 01-2025 03-2025: 1.2%▼ -2.8% vs 02-2025 04-2025: 1.2%▲ +2.3% vs 03-2025 05-2025: 1.3%▲ +2.4% vs 04-2025 06-2025: 1.4%▲ +11.1% vs 05-2025 07-2025: 1.4%▲ +0.1% vs 06-2025 08-2025: 1.9%▲ +33.4% vs 07-2025highest value 09-2025: 1.6%▼ -16.3% vs 08-2025 10-2025: 1.6%● 0.0% vs 09-2025 11-2025: 1.6%▼ -0.7% vs 10-2025 12-2025: 1.6%● 0.0% vs 11-2025 01-2026: 1.6%▼ -1.3% vs 12-2025 02-2026: 1.3%▼ -15.0% vs 01-2026 03-2026: 1.3%▼ -0.6% vs 02-2026 04-2026: 1.3%▲ +1.7% vs 03-2026 05-2026: 1.1%▼ -17.5% vs 04-2026 06-2026: 1.1%▲ +1.4% vs 05-2026 07-2026: 1.1%● 0.0% vs 06-2026 08-2026: 1.1%▼ -2.4% vs 07-2026 09-2026: 1.0%▼ -5.7% vs 08-2026lowest value 10-2026: 1.0%● 0.0% vs 09-2026lowest value
  • Equity €381 (0.1% of total assets) raises the probability
  • 1 of the last 3 late raises the probability
  • Founded in 2015 lowers the probability for this profile
  • Size: 1.6 FTE, total assets €469,684 lowers the probability for this profile
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 47, micro). Better than this share of them on solvency 19%, liquidity 46%, profitability 60%, growth against the median 5%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 05-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Equity €381 (0.1% of total assets)
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
raises risk · 1 of the last 3 late
In the bankruptcy model this factor raises the probability.
NBB · filings
lowers risk · Founded in 2015
In the bankruptcy model this factor lowers the probability for this profile.
KBO
lowers risk · Size: 1.6 FTE, total assets €469,684
In the bankruptcy model this factor lowers the probability for this profile.
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 13% of 4911 sector peers (2025).
NBB · sector comparison
Position among 4911 sector peers
Solvency
better than 13%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 01-04-2026, 121 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
121 d early
2024
18 d late
2023
43 d late
2022
29 d late
2021
31 d early
2020
4 d late
2019
31 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 13 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 18 August (4 of the last 5 filed years within 49 days of that day).
Companies Code · seven months
Position in the running window
05-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · full…
  2. Annual accounts filedfiscal year 2024 · full…
  3. Weakest financial yearnet €15,299 ▼63.6%

Key points

  • Caution: Among the weakest 13% on equitysector median €448,626 · 4,912 companies €381 View
  • Positive: 8 profitable years in a rowprofit 2025: €20,540 8 years View
  • Total assets 20256 fiscal years filed €469,684 View

By topic

Financials

Fiscal year
2025
Total assets
€469,684
Profit
€20,540
Solvency
0.1%
Total assets▼ 7.5%
Net result
20182025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 31-07-2027
  1. 01-04-2026Annual accounts filed
  2. 18-08-2025Annual accounts filed
  3. 31-12-2024Weakest financial year
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
19-08-2015
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure